Omeros Corporation

Omeros Corporation a clinical-stage biopharmaceutical company discovers develops and commercializes small-molecule and protein therapeutics and orphan indications targeting inflammation complement-mediated diseases cancers and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria complement 3 glomerulopathy and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS HSCT-TMA and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic immuno-oncologic metabolic CNS cardiovascular musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle Washington.